Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

2.

Young adults who are obese are at risk for 17 different types of cancer in the future.

3.

A study has developed molecular markers that predict meningioma recurrence.

4.

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

5.

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot